Beta Bionics, Inc. Stock Price, News & Analysis

Beta Bionics (Nasdaq: BBNX) reported third quarter 2025 results and raised full‑year guidance. Q3 net sales $27.3M (+63% YoY) with DME sales $21.0M (+45%) and PBP sales $6.2M (+178%). Gross margin was 55.5% (up 212 bps). Installed customer base reached 29,419 users (+162% YoY) with 5,334 new patient starts (+68%), ~70% from MDI. Loss from operations was $17.0M; net loss $14.2M; adjusted EBITDA was negative $12.2M. Cash and investments totaled $274.0M as of Sept 30, 2025. Management completed a glucagon PK/PD trial, expects a New Zealand feasibility trial in Q4 2025, and received Special 510(k) updates for iLet on Sept 29, 2025. Full‑year 2025 revenue guidance raised to greater than $96.5M.

Beta Bionics (Nasdaq: BBNX) will release its third quarter 2025 financial results after market close on Tuesday, October 28, 2025. Management will host a conference call and concurrent webcast the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The webcast link will be posted and archived in the company’s Investors & Events section at https://investors.betabionics.com. Phone access requires registration for dial-in details and a personal PIN via https://register-conf.media-server.com/register/BI0b27b735377640268ec22270324ddd73.

Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Wells Fargo Healthcare Conference (September 4), Morgan Stanley Global Healthcare Conference (September 8), and Baird Global Healthcare Conference (September 10).

Live webcasts will be available for the Wells Fargo and Morgan Stanley presentations through the company's investor relations website, where recordings will also be archived for future viewing.

Beta Bionics (Nasdaq: BBNX) reported strong Q2 2025 financial results, with net sales reaching $23.2 million, up 54% year-over-year. The company's installed customer base grew 200% to 24,085 users, with 4,934 new patient starts in Q2. The company achieved significant growth in both DME and PBP channels, with PBP channel sales surging 498% to $4.6 million.

Key operational metrics showed improvement with gross margin reaching 53.8%. Despite growth, the company reported a net loss of $16.9 million. Beta Bionics raised its full-year 2025 guidance, projecting revenue of $88-93 million, up from previous guidance of $82-87 million.

Strategic highlights include securing formulary agreements with major PBMs and completing dosing in the glucagon PK-PD bridging trial for their bihormonal configuration development.

Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, will release its Q2 2025 financial results on Tuesday, July 29, 2025, after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day.

Investors can access the webcast through the company's investor relations website under the "Events & Presentations" section, where it will also be archived for future viewing. For those joining by phone, registration is available through a dedicated link that will provide dial-in details and a personal pin.

[]

Beta Bionics (BBNX) announced plans to integrate its iLet Bionic Pancreas automated insulin delivery system with Abbott's upcoming dual glucose-ketone sensor in the U.S. The iLet system is notable as the first and only automated insulin delivery system making 100% automated dosing decisions, eliminating the need for carb counting or manual insulin calculations. The system currently works with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor, and this new integration represents an expansion of the existing partnership between the companies. The integration aims to enhance real-time decision-making support for diabetes patients once Abbott's new sensor becomes commercially available.

Beta Bionics (BBNX) reported strong Q1 2025 financial results and raised its annual guidance. Net sales reached $17.6 million, up 36% year-over-year, driven by growth in both DME and PBP channels. The company's installed customer base grew 291% to 19,151 users, with 3,853 new patient starts (48% increase). Despite revenue growth, the company reported increased losses with operating loss of $18.6 million and net loss of $28.7 million. Beta Bionics completed an IPO raising $206 million and secured Prime Therapeutics coverage for its iLet Bionic Pancreas. The company raised its 2025 guidance, now expecting revenue of $82-87 million and PBP channel patient starts of 22-25%. The company maintains $295.5 million in cash and investments.

Beta Bionics (BBNX), a company focused on diabetes management solutions, has announced its participation in the upcoming Bank of America Securities Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2025, at 12:35 PM ET (9:35 AM PT) in Las Vegas. Interested parties can access the live audio webcast through the company's investor relations website under the "Events & Presentations" section at investors.betabionics.com. The presentation recording will be archived on the website for future viewing.

Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, has scheduled the release of its first quarter 2025 financial results for Tuesday, May 6, 2025, after market close.

The company will host a conference call and simultaneous webcast at 4:30 PM Eastern Time (1:30 PM Pacific Time) on the same day. Investors can access the live call by dialing (888) 596-4144 with passcode 8363701. The webcast will be available in the Investors—Events & Presentations section of the company's website and will be archived for future viewing.